MacroGenics reports 27% response rate for MGC026 in phase 1 head and neck cancer trial
MGNX•MacroGenics reported a 27% response rate for MGC026 in a Phase 1 head and neck cancer trial. The company also reported manageable safety in that group, with no treatment-related discontinuations, and plans a front-line combination study in early 2027.
1. Interim trial results
MacroGenics reported interim Phase 1 results for MGC026 in advanced solid tumors, including activity in heavily pretreated patients with head and neck cancer. Safety was manageable in the head and neck cancer group, with no treatment-related discontinuations. A front-line study combining MGC026 with pembrolizumab in PD-L1-positive recurrent or metastatic head and neck cancer is planned for early 2027; enrollment continues in the Phase 1 expansion cohort, with updated results expected in mid-2027.
